Physician profile
Phaedra Lombard
NPI 1578569513
$3,705.04
in general payments reported to CMS, 2019-2025
29 companies · $865 in 2025
The $865 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $70.89 · 2021: $147 · 2022: $505 · 2023: $773 · 2024: $814 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.70 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566.00 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $431.26 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $391.21 | 2023-2025 | Veozah |
| Pfizer INC. | $356.57 | 2019-2024 | |
| Shield Therapeutics INC | $331.54 | 2024-2025 | |
| Biogen, INC. | $320.57 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $250.66 | 2022-2025 | |
| Organon LLC | $126.36 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $104.97 | 2020-2025 | |
| Agile Therapeutics, INC. | $102.82 | 2022-2024 | Twirla |
| Medtronic, INC. | $97.59 | 2022-2023 | Truclear |
| Myovant Sciences INC. | $88.91 | 2022 | |
| Therapeuticsmd, INC. | $76.34 | 2019-2022 | |
| Hologic Sales and Service, LLC | $73.15 | 2020-2024 | Thinprep 2000 Processor, Aptima, Third Wave |
| Intuitive Surgical, INC. | $40.91 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $38.56 | 2019-2023 | Injectafer |
| Dexcom, INC. | $35.07 | 2025 | Dexcom G6 Transmitter |
| Millicent US INC | $33.68 | 2025 | Intrarosa, Femring, Femlyv |
| Minerva Surgical, INC | $31.35 | 2019-2022 | |
| Coopersurgical, INC. | $30.77 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Amag Pharmaceuticals, INC. | $27.91 | 2019 | |
| Merck Sharp & Dohme LLC | $24.02 | 2019 | |
| Monaghan Medical Corporation | $21.87 | 2023 | Aerobika |
| Davol INC. | $20.47 | 2024 | Arista Ah Flexitip |
| Pharmacosmos Therapeutics INC. | $18.63 | 2024 | Monoferric |
| Applied Medical Resources Corporation | $17.80 | 2023 | |
| Scynexis, INC. | $17.23 | 2022 | |
| Exeltis, USA INC. | $16.04 | 2024 | Slynd |
| Evofem Biosciences, INC. | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phaedra Lombard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.